iShares U.S. Healthcare ETF (NY:IYH)

73.05 +1.56 (+2.18%)

Delayed Quote Updated: 1:32 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about iShares U.S. Healthcare ETF

< Previous 1 2 3 4 Next >

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? ↗

October 11, 2026

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

Via The Motley Fool

Topics ETFs

IYH Beats IXJ on Returns While Global Fund Offers Higher Yield ↗

October 06, 2026

U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles.

Via The Motley Fool

Topics ETFs

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Via The Motley Fool

Topics ETFs

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗

January 22, 2026

Via Stocktwits

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗

September 09, 2026

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.

Via The Motley Fool

Topics ETFs

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? ↗

September 08, 2026

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Via The Motley Fool

Topics ETFs

Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits ↗

September 08, 2026

Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.

Via The Motley Fool

Topics ETFs

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗

August 13, 2026

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Via The Motley Fool

Topics ETFs

IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗

August 13, 2026

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Via The Motley Fool

Topics ETFs

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗

August 01, 2026

FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences.

Via The Motley Fool

Topics ETFs

XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield? ↗

July 27, 2026

State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60.

Via The Motley Fool

Topics ETFs

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

July 20, 2026

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK ↗

June 18, 2026

The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors...

Via The Motley Fool

Topics ETFs

Health Care ETFs: XLV Delivers Low Fees and Solid Returns ↗

June 16, 2026

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026? ↗

June 16, 2026

Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles.

Via The Motley Fool

Topics ETFs

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

Via Stocktwits

Topics Artificial Intelligence

Why Did IXHL Stock Tank Over 32% Today? ↗

February 25, 2026

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

Via Stocktwits

Why Did GERN Stock Tumble 10% Pre-Market Today? ↗

February 25, 2026

Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.

Via Stocktwits

Topics Artificial Intelligence

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗

February 24, 2026

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Via Stocktwits

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Via Stocktwits

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗

February 20, 2026

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Via Stocktwits

Why Did IMUX Stock Surge 33% Pre-Market Today? ↗

February 13, 2026

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.

Via Stocktwits

Why Did Healthcare Triangle Stock Plummet 20% Today? ↗

February 06, 2026

The technology firm announced that it will implement a 1-for-60 reverse stock split of its common shares effective at 12:01 a.m. Eastern Time on February 10.

Via Stocktwits

Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗

January 22, 2026

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Via Stocktwits

Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades' ↗

November 18, 2025

Today's "Final Trades" segment focused on UnitedHealth, Thermo Fisher Scientific, iShares U.S. Healthcare ETF and Monster Beverage.

Via Benzinga

Topics ETFs

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.